[Federal Register Volume 65, Number 81 (Wednesday, April 26, 2000)]
[Notices]
[Page 24489]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-10321]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Endocrinologic and Metabolic Drugs Advisory Committee; Notice of 
Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting is 
open to the public.

    Name of Committee: Endocrinologic and Metabolic Drugs Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 19, 2000, 10 a.m. 
to 2 p.m.
    Location: Holiday Inn, Ballroom, 8120 Wisconsin Ave., Bethesda, 
MD.
    Contact Person: Kathleen R. Reedy or LaNise S. Giles, Center for 
Drug Evaluation and Research (HFD-21), Food and Drug Administration, 
5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 
1093), Rockville MD, 301-827-7001, email: [email protected], or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12536. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: The committee will hear a presentation of the data and 
rationale for the regulatory action regarding the withdrawal from 
the U.S. market of RezulinTM (troglitazone, Parke-Davis 
Pharmaceutical Research, a Division of Warner-Lambert) for the 
treatment of type 2 diabetes mellitus.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by May 15, 
2000. Oral presentations from the public will be scheduled between 
approximately 10 a.m. and 11 a.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before May 15, 2000, 
and submit a brief statement of the general nature of the evidence 
or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: April 17, 2000.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 00-10321 Filed 4-25-00; 8:45 am]
BILLING CODE 4160-01-F